Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients With Osteoarthritis of the Knee

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients With Osteoarthritis of the Knee

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Osteoarthritis; Pain
  • Focus Therapeutic Use
  • Acronyms SPRINGBOARD
  • Sponsors Eupraxia Pharmaceuticals

Most Recent Events

  • 24 Apr 2025 According to a Eupraxia Pharmaceuticals media release, Dr. Phil Conaghan, a member of the Company's OA Clinical Advisory Board, will be presenting a poster featuring data from this study at the Osteoarthritis Research Society International ("OARSI") World Congress 2025, being held April 24-27, 2025 in Incheon (Seoul), South Korea.
  • 11 Nov 2024 According to an Eupraxia Pharmaceuticals media release, data from this trial will be presented in a poster at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting, being held in Washington, D.C. from Nov 14-19, 2024.
  • 15 Oct 2024 Results published in a an Eupraxia Pharmaceuticals media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top